Literature DB >> 20332228

FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Ethan V Abel1, Andrew E Aplin.   

Abstract

The forkhead box transcription factor FOXD3 is a stemness factor that prevents the production of melanocyte progenitors from the developing neural crest; however, its role in human cancers is not known. Transformation of melanocytes gives rise to melanoma. In two thirds of melanomas, the serine/threonine kinase B-RAF is mutated to a constitutively active form. Here, we show that FOXD3 levels are upregulated following attenuation of B-RAF and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) signaling in mutant B-RAF harboring human melanoma cells. This effect was selective because FOXD3 was not upregulated following MEK inhibition in wild-type B-RAF melanoma cells and mutant B-RAF thyroid carcinoma cells. Ectopic FOXD3 expression potently inhibited melanoma cell growth without altering mutant B-RAF activation of ERK1/2. Inhibition of cell growth was due to a potent G(1) cell cycle arrest and was associated with p53-dependent upregulation of p21(Cip1). FOXD3-induced cell cycle arrest was prevented by p53 depletion and, to a lesser extent, p21(Cip1) depletion. These studies show that FOXD3 is suppressed by B-RAF, uncover a novel role and mechanism for FOXD3 as a negative cell cycle regulator, and have implications for the repression of melanocytic lineage cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332228      PMCID: PMC2848900          DOI: 10.1158/0008-5472.CAN-09-3139

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells.

Authors:  J Sutton; R Costa; M Klug; L Field; D Xu; D A Largaespada; C F Fletcher; N A Jenkins; N G Copeland; M Klemsz; R Hromas
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

2.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c.

Authors:  Richard Y M Ma; Tommy H K Tong; Alice M S Cheung; Anthony C C Tsang; Wai Ying Leung; Kwok-Ming Yao
Journal:  J Cell Sci       Date:  2005-01-25       Impact factor: 5.285

5.  The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.

Authors:  M Cheng; P Olivier; J A Diehl; M Fero; M F Roussel; J M Roberts; C J Sherr
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

6.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Authors:  Kapaettu Satyamoorthy; Gang Li; Michelle R Gerrero; Marcia S Brose; Patricia Volpe; Barbara L Weber; Patricia Van Belle; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

7.  Mutational analysis of the human p53 gene in malignant melanoma.

Authors:  M Volkenandt; U Schlegel; D M Nanus; A P Albino
Journal:  Pigment Cell Res       Date:  1991-02

8.  Suppression of BRAF(V599E) in human melanoma abrogates transformation.

Authors:  Sunil R Hingorani; Michael A Jacobetz; Gavin P Robertson; Meenhard Herlyn; David A Tuveson
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  The Brn-2 transcription factor links activated BRAF to melanoma proliferation.

Authors:  Jane Goodall; Claudia Wellbrock; Timothy J Dexter; Karen Roberts; Richard Marais; Colin R Goding
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

Authors:  M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

View more
  51 in total

1.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

2.  In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Authors:  Kevin J Basile; Ethan V Abel; Neda Dadpey; Edward J Hartsough; Paolo Fortina; Andrew E Aplin
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.

Authors:  Michele B Weiss; Ethan V Abel; Neda Dadpey; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-07-24       Impact factor: 5.852

4.  RAC1 P29S regulates PD-L1 expression in melanoma.

Authors:  Ha Linh Vu; Sheera Rosenbaum; Timothy J Purwin; Michael A Davies; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2015-09       Impact factor: 4.693

5.  Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.

Authors:  Hua Zhao; Daozhen Chen; Jiayuan Wang; Yongxiang Yin; Qiong Gao; Ye Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

6.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.

Authors:  Kaitlyn Le; Erik S Blomain; Ulrich Rodeck; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-08       Impact factor: 4.693

7.  The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Authors:  Cibele Cardoso; Rodolfo B Serafim; Akinori Kawakami; Cristiano Gonçalves Pereira; Jason Roszik; Valeria Valente; Vinicius L Vazquez; David E Fisher; Enilza M Espreafico
Journal:  Pigment Cell Melanoma Res       Date:  2018-12-16       Impact factor: 4.693

8.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

9.  Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma.

Authors:  Xiang Yuan; Jiangtu He; Fenyong Sun; Jiang Gu
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

10.  SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

Authors:  Fred M Kaplan; Curtis H Kugel; Neda Dadpey; Yongping Shao; Ethan V Abel; Andrew E Aplin
Journal:  J Biol Chem       Date:  2012-10-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.